Expected earnings - Bioxytran Inc
Source: US Earnings Reports
Bioxytran Inc (BIXT) is expected to report for Q2 2025
Bioxytran Inc
NASDAQ: BIXT
BIXT Trading
-20.25% G/L:
$0.0323 Last:
741,705 Volume:
$0.04 Open:
BIXT Latest News
March 04, 2026 03:40:00 pm
Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M
March 02, 2026 11:40:00 am
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
February 23, 2026 06:00:00 am
Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus
February 17, 2026 07:00:00 am
Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement
BIXT Stock Data
$4,667,792
87,993,039
1.18%
1
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
